Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 30, 2024 (filed September 6, 2024), details a material definitive agreement entered into by Catheter Precision, Inc. The report covers a firm commitment underwritten public offering that was priced on August 30, 2024, and closed on September 3, 2024.
Key Financial Metrics and Capital Structure
- Net Proceeds: Approximately $2.6 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Securities Issued:
- 805,900 common stock units at $1.00 per unit.
- 2,773,000 pre-funded units at $0.9999 per unit.
- Warrant Structure: Each unit includes three warrants (Series H, I, and J) exercisable at $1.00 per share with expiration dates of 6 months, 18 months, and 5 years, respectively. Pre-funded units include a pre-funded warrant exercisable at $0.0001 with no expiration.
- Overallotment: Underwriters partially exercised the 45-day option to purchase an additional 458,623 shares and corresponding warrants.
- Share Count:
- 2,656,652 shares outstanding at the close of the offering (September 3, 2024).
- 2,804,152 shares outstanding as of September 5, 2024, following additional pre-funded warrant exercises.
Material Changes
The primary material change is the significant increase in outstanding common stock and the issuance of new warrants resulting from the public offering. The company raised capital to fund operations, with the share count increasing from pre-offering levels to over 2.8 million shares within days of the closing.
Guidance, Risks, and Contingencies
- Lock-Up Agreements: The Company and its executive officers and directors are subject to a 90-day lock-up period prohibiting the sale or transfer of securities without underwriter approval.
- Beneficial Ownership Limitations: Warrant holders are restricted from exercising warrants if it would result in beneficial ownership exceeding 4.99% (or up to 9.99% with notice) of outstanding shares.
- Indemnification: The Company agreed to indemnify underwriters against certain liabilities under the Securities Act of 1933.
- Financial Outlook: The filing does not provide specific revenue guidance, profit forecasts, or cash flow projections beyond the immediate capital raise.
Investor Verification Checklist
- Verify the exact net proceeds of $2.6 million against the final closing statement to confirm actual offering expenses.
- Confirm the dilution impact of the 2,773,000 pre-funded units and the associated warrants on existing shareholders.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific covenants and representations.
- Monitor the exercise of the remaining portion of the overallotment option (if any) within the 45-day window.
- Check subsequent filings for the utilization of the raised capital and any changes in the company's liquidity position.